Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Presentation NY Valves 2025

TAVR-in-TAVR-in-SAVR With ShortCut™ and Sentinel™

Presenter: Adishwar Singh

June 27, 2025

Presentation NY Valves 2025

SAVR vs. TAVR Strategy Trials (PARTNER 3 and RHEIA)

Presenter: Didier Tchetche

June 27, 2025

Presentation NY Valves 2025

Outcomes of TAVR vs SAVR in Patients With Cardiac Amyloidosis

Presenter: Ahmed K. Mahmoud

June 26, 2025

Presentation NY Valves 2025

Durability in TAVR and SAVR: What is the Latest Data? Is SAVR data “Generic”?

Presenter: Suzanne J. Baron

June 26, 2025

Presentation NY Valves 2025

SAVR With Y-Incision Aortic Annular Enlargement Outperforms TAVR in Hemodynamics in Women With Native Aortic Stenosis

Presenter: Bo Yang

June 26, 2025

Presentation NY Valves 2025

Bioprosthetic Valve Remodelling: Optimizing Hemodynamics During TAVR in SAVR

Presenter: Fabio Sandoli de Brito

June 26, 2025

Presentation NY Valves 2025

Long Term Outcomes After TAV in SAVR: A Durable Alternative to Re-Do Surgery?

Presenter: Gregory P. Fontana

June 26, 2025

Presentation NY Valves 2025

High Risk Coronary Obstruction TAVR in SAVR

Presenter: Itsik Ben-Dor

June 25, 2025

Presentation NY Valves 2025

TAV-in-TAV-in-SAVR After M-TEER: A Complex Case Breakdown: The Matryoshka Doll Effect

Presenter: Silvia Corona

June 25, 2025

Presentation NY Valves 2025

Considerations for TAVR-First or SAVR-First Strategies in Young Patients

Presenter: Mayra Guerrero

June 25, 2025

Presentation NY Valves 2025

CT Reduces In-Hospital Complications in SAVR

Presenter: Liliane Zillner

June 25, 2025

Presentation NY Valves 2025

Transcatheter Aortic Valve Replacement (TAVR) Versus Surgical Aortic Valve Replacement (SAVR) in Low-Risk Patients at 5 Years: An Updated Meta-Analysis of Randomized Controlled Trials

Presenter: Sunny Goel

June 25, 2025

Presentation NY Valves 2024

SAVR Transaxillary Approach: Pushing the Boundaries

Presenter: Joerg Kempfert

June 07, 2024

Presentation NY Valves 2024

Transaxillary Non-Robotic SAVR – Yet Another Option

Presenter: Joerg Kempfert

June 06, 2024

Presentation NY Valves 2024

BASILICA or ShortCut for TAV-in-SAVR or TAV-in-TAV

Presenter: Philippe Genereux

June 06, 2024

Presentation NY Valves 2024

SAVR is Clearly the Gold Standard in AS Patients Under 65 Years Old

Presenter: Keith B. Allen

June 06, 2024

Presentation NY Valves 2024

SAVR After TAVR: A Dangerous Epidemic?

Presenter: Shinichi Fukuhara

June 06, 2024

Presentation NY Valves 2024

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

Presenter: Tsuyoshi Kaneko

June 06, 2024

Presentation NY Valves 2024

SAVR for the Small Annulus Patient – Surgical Trends and Perspectives

Presenter: Hendrik Treede

June 06, 2024

Presentation NY Valves 2024

SAVR Will Have a Longer Lasting Durability Than TAVR

Presenter: Stephan Windecker

June 06, 2024

Advertisement

TAVR-in-TAVR-in-SAVR With ShortCut™ and Sentinel™

SAVR vs. TAVR Strategy Trials (PARTNER 3 and RHEIA)

Outcomes of TAVR vs SAVR in Patients With Cardiac Amyloidosis

Durability in TAVR and SAVR: What is the Latest Data? Is SAVR data “Generic”?

SAVR With Y-Incision Aortic Annular Enlargement Outperforms TAVR in Hemodynamics in Women With Native Aortic Stenosis

Bioprosthetic Valve Remodelling: Optimizing Hemodynamics During TAVR in SAVR

Long Term Outcomes After TAV in SAVR: A Durable Alternative to Re-Do Surgery?

High Risk Coronary Obstruction TAVR in SAVR

TAV-in-TAV-in-SAVR After M-TEER: A Complex Case Breakdown: The Matryoshka Doll Effect

Considerations for TAVR-First or SAVR-First Strategies in Young Patients

CT Reduces In-Hospital Complications in SAVR

Transcatheter Aortic Valve Replacement (TAVR) Versus Surgical Aortic Valve Replacement (SAVR) in Low-Risk Patients at 5 Years: An Updated Meta-Analysis of Randomized Controlled Trials

SAVR Transaxillary Approach: Pushing the Boundaries

Transaxillary Non-Robotic SAVR – Yet Another Option

BASILICA or ShortCut for TAV-in-SAVR or TAV-in-TAV

SAVR is Clearly the Gold Standard in AS Patients Under 65 Years Old

SAVR After TAVR: A Dangerous Epidemic?

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

SAVR for the Small Annulus Patient – Surgical Trends and Perspectives

SAVR Will Have a Longer Lasting Durability Than TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content